Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Convertible Debt (2021 - 2022)

bioAffinity Technologies has reported Convertible Debt over the past 2 years, most recently at $325000.0 for Q4 2022.

  • Quarterly Convertible Debt fell 87.5% to $325000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $325000.0 through Dec 2022, down 87.5% year-over-year, with the annual reading at $325000.0 for FY2022, 87.5% down from the prior year.
  • Convertible Debt was $325000.0 for Q4 2022 at bioAffinity Technologies, down from $2.6 million in the prior quarter.
  • Over five years, Convertible Debt peaked at $2.6 million in Q4 2021 and troughed at $325000.0 in Q4 2022.